BioNTech plans to return €2bn to shareholders through share buybacks and a special dividend following the commercial success of its Covid-19 vaccine, the company said on Wednesday.
The German biotech, which launched the first Covid-19 vaccine in partnership with Pfizer, said it would also boost research and development spending by 50 per cent to €1.4bn to €1.5bn, as it seeks to develop a new range of drugs based on mRNA technology.
“To continue our industry leadership, we intend to build on our 2021 success and rapidly advance multiple programs, including our mRNA-based immunotherapies, cell therapies, and bi-specific antibodies,” said Ugur Sahin, BioNTech’s co-founder and chief executive.
您已閱讀43%（696字），剩餘57%（915字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。